NF-κB Signaling in Tumor Pathways Focusing on Breast and Ovarian Cancer

被引：30

作者：

Devanaboyina, Monika ^{[1
]}

Kaur, Jasskiran ^{[1
]}

Whiteley, Emma ^{[1
]}

Lin, Leslie ^{[1
]}

Einloth, Katelyn ^{[1
]}

Morand, Susan ^{[1
]}

Stanbery, Laura ^{[2
]}

Hamouda, Danae ^{[1
]}

Nemunaitis, John ^{[2
]}

机构：

[1] Univ Toledo, Dept Med, Coll Med & Life Sci, Toledo, OH USA

[2] Gradalis Inc, Carrollton, TX 75006 USA

来源：

ONCOLOGY REVIEWS | 2022年 / 16卷

关键词：

ovarian cancer; breast cancer; NF kappa B; immunotherapy; tumor signaling; inflammatory signaling; HISTONE DEACETYLASE INHIBITORS; UP-REGULATE PD-L1; CROSS-TALK; PHOSPHATIDYLINOSITOL; 3-KINASE; ESTROGEN-RECEPTOR; TNF-ALPHA; C-REL; EXPRESSION; ACTIVATION; IMMUNOTHERAPY;

D O I：

10.3389/or.2022.10568

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immune disorders and cancer share a common pathway involving NF-kappa b signaling. Through involvement with GM-CSF, NF-kappa B can contribute to proliferation and activation of T- and B- cells as well as immune cell migration to sites of inflammation. In breast cancer, this signaling pathway has been linked to resistance with endocrine and chemotherapies. Similarly, in ovarian cancer, NF-kappa B influences angiogenesis and inflammation pathways. Further, BRCA1 signaling common to both breast and ovarian cancer also has the capability to induce NF-kappa B activity. Immunotherapy involving NF-kappa B can also be implemented to combat chemoresistance. The complex signaling pathways of NF-kappa B can be harnessed for developing cancer therapeutics to promote immunotherapy for improving patient outcomes.

引用

页数：10

共 115 条

[1] Tissue transglutaminase as a central mediator in inflammation-induced progression of breast cancer [J].

Agnihotri, Navneet ;

Kumar, Santosh ;

Mehta, Kapil .

BREAST CANCER RESEARCH, 2013, 15 (01)

[2] Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN) [J].

Ahern, Elizabeth ;

Cubitt, Annette ;

Ballard, Emma ;

Teng, Michele W. L. ;

Dougall, William C. ;

Smyth, Mark J. ;

Godbolt, David ;

Naidoo, Rishendran ;

Goldrick, Amanda ;

Hughes, Brett G. M. .

TRIALS, 2019, 20 (01)

[3] Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer [J].

Alberti, C. ;

Pinciroli, P. ;

Valeri, B. ;

Ferri, R. ;

Ditto, A. ;

Umezawa, K. ;

Sensi, M. ;

Canevari, S. ;

Tomassetti, A. .

ONCOGENE, 2012, 31 (37) :4139-4149

[4] PD-L1 expression is regulated by both DNA methylation and NF-κB during EMT signaling in non-small cell lung carcinoma [J].

Asgarova, A. ;

Asgarov, K. ;

Godet, Y. ;

Peixoto, P. ;

Nadaradjane, A. ;

Boyer-Guittaut, M. ;

Galaine, J. ;

Guenat, D. ;

Mougey, V. ;

Perrard, J. ;

Pallandre, J. R. ;

Bouard, A. ;

Balland, J. ;

Tirole, C. ;

Adotevi, O. ;

Hendrick, E. ;

Herfs, M. ;

Cartron, P. F. ;

Borg, C. ;

Hervouet, E. .

ONCOIMMUNOLOGY, 2018, 7 (05)

[5]

Barve M., 2016, BIOMED GENET GENOMIC, V1, DOI [10.15761/bgg.1000116, DOI 10.15761/BGG.1000116, 10.15761/BGG.1000116]

[6] Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression [J].

Basseres, D. S. ;

Baldwin, A. S. .

ONCOGENE, 2006, 25 (51) :6817-6830

[7] Functions of NF-κB1 and NF-κB2 in immune cell biology [J].

Beinke, S ;

Ley, SC .

BIOCHEMICAL JOURNAL, 2004, 382 :393-409

[8] Mutual cross-talk between reactive oxygen species and nuclear factor-kappa B: molecular basis and biological significance [J].

Bubici, C. ;

Papa, S. ;

Dean, K. ;

Franzoso, G. .

ONCOGENE, 2006, 25 (51) :6731-6748

[9] A BRCA1 deficient, NFκB driven immune signal predicts good outcome in triple negative breast cancer [J].

Buckley, Niamh E. ;

Haddock, Paula ;

Simoes, Ricardo De Matos ;

Parkes, Eileen ;

Irwin, Gareth ;

Emmert-Streib, Frank ;

McQuaid, Stephen ;

Kennedy, Richard ;

Mullan, Paul .

ONCOTARGET, 2016, 7 (15) :19884-19896

[10] Denosumab for the treatment of bone metastases in advanced breast cancer [J].

Casas, Ana ;

Llombart, Antonio ;

Martin, Miguel .

BREAST, 2013, 22 (05) :585-592

← 1 2 3 4 5 6 7 8 9 10 →